Linked Life Data

15623610

Source:http://linkedlifedata.com/resource/pubmed/id/15623610

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
24
pubmed:dateCreated
2004-12-29
pubmed:abstractText
Use of surrogate end point biomarkers in phase II trials may help select agents that appear to have activity and might be evaluated in future phase III definitive trials of breast cancer prevention. We performed a pilot clinical trial to establish the logistics for a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with novel imaging techniques and candidate surrogate end point biomarkers for activity. We chose tamoxifen to establish proof of principal with a known effective agent.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
8332-40
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:15623610-Adult, pubmed-meshheading:15623610-Aged, pubmed-meshheading:15623610-Breast Neoplasms, pubmed-meshheading:15623610-Carcinoma, Ductal, Breast, pubmed-meshheading:15623610-Carcinoma, Lobular, pubmed-meshheading:15623610-Chemoprevention, pubmed-meshheading:15623610-Feasibility Studies, pubmed-meshheading:15623610-Female, pubmed-meshheading:15623610-Humans, pubmed-meshheading:15623610-Magnetic Resonance Imaging, pubmed-meshheading:15623610-Mammography, pubmed-meshheading:15623610-Middle Aged, pubmed-meshheading:15623610-Models, Biological, pubmed-meshheading:15623610-Pilot Projects, pubmed-meshheading:15623610-Prospective Studies, pubmed-meshheading:15623610-Risk Factors, pubmed-meshheading:15623610-Selective Estrogen Receptor Modulators, pubmed-meshheading:15623610-Tamoxifen, pubmed-meshheading:15623610-Tumor Markers, Biological
pubmed:year
2004
pubmed:articleTitle
A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity.
pubmed:affiliation
Breast Cancer Program, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA. vstearn1@jhmi.edu
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Research Support, N.I.H., Extramural